Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Immunoprecise Antibodies Ltd (IPA)

  • Business News
  • July 24, 2025, 12:22 UTC
  • 2

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Market reaction Comment Full text

Trinity Biotech plc (TRIB)

  • Business News
  • July 24, 2025, 12:20 UTC
  • 2

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market

Market reaction Comment Full text

Hyperfine Inc (HYPR)

  • Business News
  • July 24, 2025, 12:16 UTC
  • 2

Hyperfine Swoop® AI-Powered Portable MRI System Showcased in Clinical Studies Designed to Broaden Access to Dementia Care

Market reaction Comment Full text

Coya Therapeutics Inc (COYA)

  • Business News
  • July 24, 2025, 12:15 UTC
  • 2

CoyaTherapeutics - Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease

Market reaction Comment Full text

Aditx Therapeutics Inc (ADTX)

  • Business News
  • July 24, 2025, 12:15 UTC
  • 1

Aditxt’s Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Market reaction Comment Full text

Coya Therapeutics Inc (COYA)

  • Business News
  • July 24, 2025, 12:15 UTC
  • 3

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease

Market reaction Comment Full text

Candel Therapeutics Inc (CADL)

  • Business News
  • July 24, 2025, 12:06 UTC
  • 1

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Market reaction Comment Full text

Novavax Inc (NVAX)

  • Business News
  • July 24, 2025, 12:06 UTC
  • 1

Novavaxs H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Market reaction Comment Full text

Vir Biotechnology (VIR)

  • Business News
  • July 24, 2025, 12:05 UTC
  • 1

Vir Biotechnology - Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Market reaction Comment Full text

Vir Biotechnology (VIR)

  • Business News
  • July 24, 2025, 12:05 UTC
  • 1

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Market reaction Comment Full text
  • Previous
  • 19
  • 20
  • 21
  • 22
  • 23
  • Next

Search

News categories

  • Technical Exchange News(9650)
  • Event(407)
  • SEC News(158386)
  • FDA Approval(9114)
  • Company Report(721)
  • Business News(107602)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin